Amol Akhade: ASCO 2025 mCRPC Guideline Update – What’s new in sequencing
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, posted on X:
“Treatment Sequencing:
ASCO 2025 mCRPC Guideline Update. What’s new in sequencing? Let’s break it down! Post-ADT only.
• BRCA1/2+: PARPi+ARPI combo (Talazoparib/Enza, Olaparib/Abi)
• HRR−: Abi/Enza or Docetaxel
• Bone-only: Add Radium-223
• MSI-H: Pembrolizumab
After ARPI
• BRCA+: Olaparib
• HRR−: Docetaxel > Cabazitaxel
• Avoid 2nd ARPI due to cross-resistance
Post-Docetaxel
• ARPI or Cabazitaxel
• BRCA+: continue PARPi
• MSI-H: Pembrolizumab
After Triplet (ADT+ARPI+Docetaxel)
• PSMA+: 177Lu-PSMA-617
• BRCA+: Olaparib or Rucaparib
• HRR−: Cabazitaxel or Radium-223
• Consider platinum for aggressive variants.”
Title: Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.
Authors: Rohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, R. Bryan Rumble, Mary-Ellen Taplin, Terry M. Kungel, Daniel Herchenhorn, Tian Zhang, Kathryn E. Beckermann, Neha Vapiwala, Michael A. Carducci, Paul Celano, Sebastien J. Hotte, Arnab Basu, Hala Borno, Alan H. Bryce, Peng Wang, Elizabeth Wulff-Burchfield, Lisa Bodei, Andrew Loblaw, Robert J. Hamilton, Hamid Emamekhoo, Thomas A. Hope, Huan He, M. Hassan Murad, Hongfang Liu, James Elbert Williams Jr, Rahul A. Parikh
Read The Full Article at Journal of Clinical Oncology.
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023